Relationship of asprosin and diabetes: a meta-analysis
Xiandong Zeng1, Xin Sun2, Wei He3
1Department of Oncological Surgery, Fourth People's Hospital of Shenyang, Shenyang, P.R. China.
Background:
Diabetes characterized by chronic hyperglycemia, has become a serious hazard to human health in the recent decades. Previous research suggests that asprosin may contribute to the development of diabetes by regulating glucose homeostasis, appetite, insulin secretion, and insulin sensitivity. Although some studies have shown that asprosin levels are higher in patients with diabetes than in healthy individuals, the association between asprosin levels and diabetes remains controversial.
Aim:
This meta-analysis aimed to assess asprosin levels in patients with diabetes and in healthy individuals.
Methods:
We searched the following electronic databases: Web of Science, ScienceDirect, PubMed, and Willy. The title or abstract uses the following search term: "diabetes" is used in combination with the term "asprosin." The meta-analysis results are presented as standardized mean differences (SMDs) with corresponding 95% confidence intervals (CIs).
Results:
Fourteen articles were included in this meta-analysis. In our meta-analysis, the asprosin level in patients with diabetes was significantly higher than that in healthy controls (SMD: 0.95, 95% CI [0.66, 1.24]). Moreover, there was a significant difference in the asprosin levels between patients with diabetes without complication and those with complication (SMD: 0.81, 95% CI [0.33, 1.29]).
Conclusions:
This systematic review is the first to evaluate the relationship between asprosin levels and diabetes. The asprosin levels were significantly higher in patients with diabetes.
Clinical Trial Number:
Not applicable.
Related Concept Videos
Psychoneuroimmunology: Diabetes and Cancer
Oral Hypoglycemic Agents: Biguanides and Glitazones
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Diabetes Mellitus: Type 2 and Gestational
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
Oral Hypoglycemic Agents: Sulfonylureas


